Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 17:15:1411631.
doi: 10.3389/fphar.2024.1411631. eCollection 2024.

The effects of standardized cannabis products in healthy volunteers and patients: a systematic literature review

Nadia A Leen  1 , Mikael A Kowal  1 , Albert Batalla  2 , Matthijs G Bossong  1   2
Affiliations

The effects of standardized cannabis products in healthy volunteers and patients: a systematic literature review

Nadia A Leen et al. Front Pharmacol. .

Abstract

Introduction: There is growing recognition of the potential of cannabis to treat various medical conditions and symptoms, such as chronic pain, spasticity, and epilepsy. However, one of the biggest challenges is the assurance of a standardized cannabis product that contains a consistent amount of its main psychoactive substances delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), and which is compliant with predetermined specifications for these compounds. This is crucial not only to ensure consistent cannabis quality and dosage for patients but also to effectively translate research findings into clinical practice.

Methods: This systematic literature review provides an overview of the effects of standardized cannabis products from Bedrocan, a leading Dutch producer of pharmaceutical-quality standardized medicinal cannabis.

Results: Cannabis administration to healthy volunteers induces dose-dependent acute effects, such as rapidly rising THC and CBD blood concentrations, the subjective experience of high and anxiety, slower reaction time and impaired attention, learning and working memory. Patient studies suggest that treatment with medicinal cannabis reduces pain intensity across a broad range of chronic pain-related medical conditions. Medicinal cannabis showed a mild safety profile, with minor and transient side effects, such as feeling high, coughing and mental confusion. The strength of acute effects, the experience of side effects and the drop-out rate in patient studies may depend on cannabis dose, cannabis composition (CBD:THC ratio), and cannabis use history of participants.

Conclusion: Safety and efficacy of standardized medicinal cannabis products should be further investigated in randomized clinical trials with sufficient sample size, with particular focus on cannabis dose and composition, age and differences between males and females.

Keywords: Bedrocan; cannabidiol (CBD); chronic pain; medicinal cannabis; side effects; tetrahydrocannabinol (THC).

PubMed Disclaimer

Conflict of interest statement

Authors NL, MK, and MB were employed by Bedrocan International BV. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

References

    1. Almog S., Aharon-Peretz J., Vulfsons S., Ogintz M., Abalia H., Lupo T., et al. (2020). The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: a randomized, double-blinded, placebo-controlled trial. Eur. J. Pain (United Kingdom) 24 (8), 1505–1516. 10.1002/ejp.1605 - DOI - PMC - PubMed
    1. Arkell T. R., Kevin R. C., Vinckenbosch F., Lintzeris N., Theunissen E., Ramaekers J. G., et al. (2022). Sex differences in acute cannabis effects revisited: results from two randomized, controlled trials. Addict. Biol. 27 (2), e13125. 10.1111/adb.13125 - DOI - PMC - PubMed
    1. Arkell T. R., Vinckenbosch F., Kevin R. C., Theunissen E. L., McGregor I. S., Ramaekers J. G. (2020). Effect of cannabidiol and ?9-Tetrahydrocannabinol on driving performance: a randomized clinical trial. JAMA - J. Am. Med. Assoc. 324 (21), 2177–2186. 10.1001/jama.2020.21218 - DOI - PMC - PubMed
    1. Arzimanoglou A., Brandl U., Cross J. H., Gil-Nagel A., Lagae L., Landmark C. J., et al. (2020). Epilepsy and cannabidiol: a guide to treatment. Epileptic Disord. 22 (1), 1–14. 10.1684/EPD.2020.1141 - DOI - PubMed
    1. Aviram J., Atzmony D., Eisenberg E. (2022). Long-term effectiveness and safety of medical cannabis administered through the metered-dose Syqe Inhaler. Pain Rep. 7 (3), E1011. 10.1097/PR9.0000000000001011 - DOI - PMC - PubMed

Publication types

LinkOut - more resources